Leerink Partnrs Weighs in on Guardant Health Q4 Earnings

Guardant Health, Inc. (NASDAQ:GH) – Investment analysts at Leerink Partnrs upped their Q4 2024 earnings per share estimates for shares of Guardant Health in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.73) per share for the quarter, up from their prior forecast of ($0.76). The consensus estimate for Guardant Health’s current full-year earnings is ($3.44) per share. Leerink Partnrs also issued estimates for Guardant Health’s Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.54) EPS and FY2026 earnings at ($2.86) EPS.

GH has been the topic of a number of other research reports. Barclays began coverage on shares of Guardant Health in a report on Thursday. They set an “overweight” rating and a $60.00 price objective on the stock. Leerink Partners decreased their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Sanford C. Bernstein dropped their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Guggenheim restated a “buy” rating on shares of Guardant Health in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Sixteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.81.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $48.60 on Thursday. Guardant Health has a 52-week low of $15.81 and a 52-week high of $49.86. The company has a market cap of $6.01 billion, a P/E ratio of -11.46 and a beta of 1.28. The stock’s 50-day moving average is $34.89 and its 200-day moving average is $29.39.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.73) EPS.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,548 shares of company stock worth $179,782. Insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently modified their holdings of GH. R Squared Ltd bought a new position in Guardant Health during the fourth quarter valued at approximately $26,000. JNBA Financial Advisors purchased a new position in shares of Guardant Health during the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in Guardant Health during the 3rd quarter worth approximately $34,000. Quarry LP purchased a new position in Guardant Health during the second quarter valued at approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Guardant Health in the second quarter worth approximately $71,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.